COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ
G.P. Boland, Nigel Bundred(Manchester Academic Health Science Centre)
Cited by 198
Related Papers
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|337
Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways
|JNCI Journal of the National Cancer Institute|2007|311
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
|Annals of Oncology|2010|280
Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast
|British Journal of Cancer|2003|16